SCHEMBL107828

SCHEMBL107828

Cc1cnc(C(=O)NN)s1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 2/20 0.52
HDAC3 O15379 2/20 0.45
HDAC1 Q13547 2/20 0.45
NPC1 O15118 6/20 0.44
RAB9A P51151 6/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
NOS1 P29475 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.42
FDPS P14324 1/20 0.42
ALDH1A1 P00352 2/20 0.42
PKM P14618 3/20 0.41
POLB P06746 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
P2RX7 Q99572 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30015722 0.98 SMYD3 (0.51) SMYD3HDAC3HDAC1NPC1RAB9A
SCHEMBL12124245 0.82 SMYD3 (0.47) SMYD3HDAC3HDAC1NPC1RAB9A
SCHEMBL2629375 0.82 SMYD3 (0.47) SMYD3HDAC3HDAC1NPC1RAB9A
SCHEMBL12124194 0.81 SMYD3 (0.50) SMYD3HDAC3HDAC1NPC1RAB9A
SCHEMBL12124304 0.81 SMYD3 (0.47) SMYD3HDAC3HDAC1NPC1RAB9A
SCHEMBL19102444 0.80 SMYD3 (0.46) SMYD3HDAC3HDAC1NPC1RAB9A
SCHEMBL12181522 0.80 SMYD3 (0.46) SMYD3HDAC3HDAC1NPC1RAB9A
SCHEMBL12124542 0.78 SMYD3 (0.44) SMYD3HDAC3HDAC1NPC1RAB9A
SCHEMBL20190429 0.78 SMYD3 (0.48) SMYD3HDAC3HDAC1NPC1RAB9A
SCHEMBL12124298 0.78 POLB (0.54) SMYD3HDAC3HDAC1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12312345-B2 Fluoroalkyl-oxadiazoles and uses thereof TENAYA THERAPEUTICS, INC. (US) 2025-05-27 US disclosed
US-20240182462-A1 FLUOROALKYL-OXADIAZOLES AND USES THEREOF TENAYA THERAPEUTICS, INC. 2024-06-06 US disclosed
US-11926622-B2 Fluoroalkyl-oxadiazoles and uses thereof TENAYA THERAPEUTICS, INC. (US) 2024-03-12 US disclosed
US-20230143804-A1 FLUOROALKYL-OXADIAZOLES AND USES THEREOF TENAYA THERAPEUTICS, INC. 2023-05-11 US disclosed
US-20230143804-A1 FLUOROALKYL-OXADIAZOLES AND USES THEREOF TENAYA THERAPEUTICS, INC. 2023-05-11 US disclosed
US-20230143804-A1 FLUOROALKYL-OXADIAZOLES AND USES THEREOF TENAYA THERAPEUTICS, INC. 2023-05-11 US disclosed
US-11578066-B1 Fluoroalkyl-oxadiazoles and uses thereof TENAYA THERAPEUTICS, INC. (US) 2023-02-14 US disclosed
US-11578066-B1 Fluoroalkyl-oxadiazoles and uses thereof TENAYA THERAPEUTICS, INC. (US) 2023-02-14 US disclosed
EP-4076448-A1 FLUOROALKYL-OXADIAZOLES AND USES THEREOF Tenaya Therapeutics, Inc. (US) 2022-10-26 EP disclosed
CN-114980887-A Fluoroalkyl-oxadiazoles and their use 特纳亚治疗股份有限公司 2022-08-30 CN disclosed
EP-2424869-B1 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS GLAXO GROUP LTD (GB) 2016-06-22 EP disclosed
EP-2424869-B1 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS GLAXO GROUP LTD (GB) 2016-06-22 EP disclosed
WO-2014151784-A1 COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES IRM LLC (BM) 2014-09-25 WO disclosed
US-8501946-B2 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators GLAXO GROUP LIMITED (GB) 2013-08-06 US disclosed
US-8501946-B2 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators GLAXO GROUP LIMITED (GB) 2013-08-06 US disclosed
US-20120157436-A1 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS GLAXO GROUP LIMITED (GB) 2012-06-21 US disclosed
US-20120157436-A1 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS GLAXO GROUP LIMITED (GB) 2012-06-21 US disclosed
EP-2424869-A1 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS Glaxo Group Limited (GB) 2012-03-07 EP disclosed
WO-2010125102-A1 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS GLAXO GROUP LIMITED (GB) 2010-11-04 WO disclosed
WO-2010125102-A1 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS GLAXO GROUP LIMITED (GB) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11926622-B2 Fluoroalkyl-oxadiazoles and uses thereof HDAC6, HDAC1, HDAC3 SMYD3 444/4885HDAC3 3/4885HDAC1 2/4885
US-20240182462-A1 FLUOROALKYL-OXADIAZOLES AND USES THEREOF HDAC6, HDAC1, HDAC3 SMYD3 444/4885HDAC3 3/4885HDAC1 2/4885
US-12312345-B2 Fluoroalkyl-oxadiazoles and uses thereof HDAC6, HDAC1, HDAC3 SMYD3 444/4885HDAC3 3/4885HDAC1 2/4885
US-11578066-B1 Fluoroalkyl-oxadiazoles and uses thereof HDAC6, HDAC1, HDAC3 SMYD3 444/4885HDAC3 3/4885HDAC1 2/4885
US-20230143804-A1 FLUOROALKYL-OXADIAZOLES AND USES THEREOF HDAC6, HDAC1, HDAC3 SMYD3 727/4885HDAC3 3/4885HDAC1 2/4885
US-20120157436-A1 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS P2RX7, P2RX6, P2RX3 SMYD3 4641/4885HDAC3 1235/4885HDAC1 2175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.